Skip to main content

IncellDx Inks Dx Distribution Deal in India

NEW YORK (GenomeWeb) – Premas Life Sciences announced today that it has signed an agreement to acquire the exclusive distribution rights in India to IncellDx's portfolio of immune-oncology and oncology diagnostic products.

Included in the deal are IncellDx's OncoTect single-cell assay for quantifying PD-L1 on tumor cells and immune cell subtypes; its single-cell assay for HPV E6/E7 mRNA detection in cervical samples; and its IncellPrep single-cell preparation kit for solid tissues including tumors.

Additional terms were not disclosed.

"IncellDx's OncoTect assays ... offer revolutionary single-cell proteomic and genomics marker-based diagnostics and, more importantly, a prognostic solution for early detection and staging for cancer patients with more targeted immuno-onco therapies," Premas Managing Director Praveen Gupta said in a statement. "India's cancer burden is increasing, and IncellDx offers a perfect path for highly effective companion diagnostics."

Late last year, IncellDx inked a deal for the Chinese distribution rights to its products with GIMDx. Earlier this year, it partnered with Celsee on the commercialization of several diagnostic products including a 20-marker lung cancer genomics and proteomics panel and a cell-based NIPT assay.